GENERAL COMMENTS

Summary:
In this study, the authors propose a randomized, open label multicentre trial of ZA versus ZA plus standard of care for the prevention of significant femoral head collapse in children with Perthes Disease. The study is 24 months in duration, with an anticipated 100 children to enrol and 80 to complete the study. The primary outcome is the Deformity Index at 24 months, following five, three-monthly doses of ZA 0.025 mg/kg (at baseline, 3, 6, 9 and 12 months). A number of other efficacy and safety outcomes are also being tested throughout the trial and at 24 months. The standard of care consists of calcium and vitamin D supplementation to both groups as well as orthopedic recommendations at the discretion of the treating orthopedic surgeon, such as non-weight-bearing. Comments: 1.
The abstract should include the dose to be used of ZA and frequency 2.
The abstract refers to 12 months of ZA but a 24 month study. It was not clear from the abstract, what is the actual duration of this study. The following should be clear in the abstract, as well as the text. a.
Duration of the entire study: enrollment period plus trial period for the entire study. The enrollment period is not stated anywhere in the paper. b.
Duration of the study for a given participant: trial period per patient. It appears that there is 12 months of ZA given every 3 months, followed by a 12 month observation period. 3.
Introduction: Paragraph 3. One of the sentences states: Two large multi-centre trials represent landmark studies so far, and the overall results…There is only one reference here and it is a paper by Kim that is more of a review article. Instead, please cite the actual two papers that represent the two multi-centre trials referred to in this sentence. 4.
In the introduction, there should be more weight behind the rationale for using ZA. ZA will decrease bone turnover at a skeletal site that is already damaged, which raises theoretical concern. On the other hand, the use of ZA in animal models arising from Little/Munns groups is quite compelling, yet the animal studies receive only a vague statement to say that they support the hypothesis that ZA might work. Suggest rounding out the motivation behind using ZA specifically in this trial.
5.
Exclusion criteria: vitamin D deficiency and hypocalcemia are typical exclusion criteria for safety reasons; these should be part of the exclusion criteria, clearly defined. 6.
Evaluation of the primary outcome: Is it sufficient to have a single reader evaluate the primary outcome? A more robust approach is to have more than one reader; either two readers who reach consensus together; or better, two readers initially blinded to the results of each other, with then resolution by consensus or by a third reader. Highly recommend a multi-read approach to minimize bias. 7.
Sample size calculation -is an anticipated difference of 25% between the two groups clinically as well as statistically significant? If so, what is the justification for the claim that this is a clinically significant difference? 8.
Pilot data -on page 7 it is mentioned that there was pilot data generated -has this been published? The pilot data should be cited. Was the same dose and interval of ZA used in the pilot study as in the full trial? Also, it sounds like the pilot trial is finished so this pilot study should be referred to in the past tense. 9.
Verb tenses throughout -sometimes the paper is written in the past tense, as if the study has already finished enrolling or has been completed, and other times it is written as if the study is underway. Please align verbs with the actual timeline for the studywhere is the study in the course of its execution? For example, it says that ZA "was given"…page 7 of the ZA treatment section…This makes it sound like the trial is over. I would include a separate paragraph with the following header "Current Status of the Trial", and then use verbs that reflect that status throughout. 10.
Vitamin D and calcium supplementation -this is first referred to vaguely under standard of care with no mention of dosing. It is then referred to after the ZA treatment section with a specific dose stated. Overall I find the sections on calcium and vitamin D supplementation to be quite vague. How is the calcium intake (diet and supplementation both) assessed? It should be done systemically with a quantifiable method if calcium intake is to be manipulated as stated. 333 IU vitamin D per day is not a big dose and is lower than the typical standard recommended amount of 400 IU/day; some patients will need even higher doses than this for vitamin D adequacy. How was 333 IU/day arrived at as the optimal dose for this trial? What if this is insufficient to maintain adequate levels? What level of adequacy is being targeted? Since vitamin D and calcium are being manipulated in this trial, it is important to clearly state the methods behind the supplementation for both the ZA and the SOC (standard of care) groups. 11.
How is compliance with vitamin D and calcium supplementation being quantified? Understand that it will be important when reporting this trial's results that calcium and vitamin D intake are similar between the two groups at baseline and during the trial, otherwise these could be confounders which influence the trial's results. 12.
Why use the FACES pain scale and not the FACES-revised scale? 13.
Measurements: These should be divided into safety and efficacy outcomes. It should be clearly stated which outcomes undergo central analysis and which undergo local analysis. Recommend central analysis wherever possible, particularly outcomes that can be delivered to a central site (including x-rays). 14.
How was a cut-off of greater than or equal to 3 SD for BMD parameters and a ZA stopping indication determined? In the pilot study, did this ever happen? If yes, was the frequency of this event considered in the sample size calculation and projected attrition rate? 15. 
Q2
Duration of the study for a given participant: trial period per patient. It appears that there is 12 months of ZA given every 3 months, followed by a 12 month observation period. Q3 Introduction: Paragraph 3. One of the sentences states: Two large multi-centre trials represent landmark studies so far, and the overall results…There is only one reference here and it is a paper by Kim that is more of a review article. Instead, please cite the actual two papers that represent the two multi-centre trials referred to in this sentence.
-This has been addressed: Two large multicentre trials represent the landmark studies so far, and the overall results of current treatment at best are modest(4, 12).
Q4
-The paragraph in the Introduction is revised: Due to the lack of reliable surgical and non-surgical treatment, research into medical therapy with bisphosphonates has intensified in recent years. Ischaemic necrosis of an immature femoral head leads to an unbalanced repair response, in which there is predominant bone resorption resulting in excessive bone loss compared to new bone formation(7). Anti-resorptive properties of bisphosphonate may be able to reduce the osteoclastic resorption in PD, and thus preserve femoral head strength and shape(6, 14, 15). The preserved femoral head bone could then act as a scaffold upon which new bone is formed. Clinical studies in osteonecrotic conditions and pre-clinical animal models of PD support this hypothesis with preservation of femoral head shape following revascularisation(16-20). We designed the first randomized controlled trial of bisphosphonate therapy in PD, to compare the two treatment arms a) standard care plus Zoledronic Acid (ZA) and b) standard care.
Q5 Exclusion criteria: vitamin D deficiency and hypocalcemia are typical exclusion criteria for safety reasons; these should be part of the exclusion criteria, clearly defined. Q8 Pilot data -on page 7 it is mentioned that there was pilot data generated -has this been published? The pilot data should be cited. Was the same dose and interval of ZA used in the pilot study as in the full trial? Also, it sounds like the pilot trial is finished so this pilot study should be referred to in the past tense. Q9 Verb tenses throughout -sometimes the paper is written in the past tense, as if the study has already finished enrolling or has been completed, and other times it is written as if the study is underway. Please align verbs with the actual timeline for the study -where is the study in the course of its execution? For example, it says that ZA "was given"…page 7 of the ZA treatment section…This makes it sound like the trial is over. I would include a separate paragraph with the following header "Current Status of the Trial", and then use verbs that reflect that status throughout.
-Header added before the title 'Intervention':
Current status of trial-The Study is ongoing. To date 70 children have been randomised.
-the following sentence for ZA treatment is corrected:
The dosage of 0.025 mg/kg is given at a 3-monthly interval for a total of five doses.
Q10
Vitamin D and calcium supplementation -this is first referred to vaguely under standard of care with no mention of dosing. It is then referred to after the ZA treatment section with a specific dose stated. Overall I find the sections on calcium and vitamin D supplementation to be quite vague. How is the calcium intake (diet and supplementation both) assessed? It should be done systemically with a quantifiable method if calcium intake is to be manipulated as stated. 333 IU vitamin D per day is not a big dose and is lower than the typical standard recommended amount of 400 IU/day; some patients will need even higher doses than this for vitamin D adequacy. How was 333 IU/day arrived at as the optimal dose for this trial? What if this is insufficient to maintain adequate levels? What level of adequacy is being targeted? Since vitamin D and calcium are being manipulated in this trial, it is important to clearly state the methods behind the supplementation for both the ZA and the SOC (standard of care) groups. 
Q14
How was a cut-off of greater than or equal to 3 SD for BMD parameters and a ZA stopping indication determined? In the pilot study, did this ever happen? If yes, was the frequency of this event considered in the sample size calculation and projected attrition rate?
-The cut off of 3SD for BMD was that considered by the investigators to be significantly high to require withdrawal from the study. Such a value was never attained during the pilot study and as such we did not take this occurrence into calculation of sample size.
